Recent advances in the management of chronic heart failure.
A number of newer therapeutic agents are available for the treatment of refractory heart failure. These agents possess either vasodilating, positive inotropic, or combined vasodilating and inotropic properties. In appropriate subsets of patients, these agents have the potential to produce clinical improvement and improvement in cardiac function.
D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002908:Chronic Disease; D003327:Coronary Disease / Q000188:drug therapy; D004071:Digitalis Glycosides / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D009200:Myocardial Contraction / Q000187:drug effects; D011379:Prognosis; D013268:Stimulation, Chemical; D014665:Vasodilator Agents / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D004071:Digitalis Glycosides; D014665:Vasodilator Agents